We deployed $2.3 billion of cash in 2020 for royalties and related assets. We deployed $2.3 billion of cash in 2020 for new royalties and related assets. 7We conduct extensive due diligence when evaluating potential new opportunities. Our right to receive royalties is perpetual. We estimate that our royalties will substantially end in 2033. We added IDHIFA to our portfolio in June 2020. We added Tazverik to our portfolio in November 2019. Therefore, competition to acquire such assets is intense. The biopharmaceutical industry is a highly competitive and rapidly evolving industry. The length of any product's commercial life cannot be predicted. We believe that the Manager's relations with its employees are satisfactory. Our Internet site is www.royaltypharma.com. As a result, we may not be able to continue to grow as we have in the past, or at all. Our business is subject to interest rate and foreign exchange risk. This could negatively impact our results of operation for a given period. 24Marketers of products that generate our royalties are outside of our control. Such reports and disclosures may become publicly available. However, there is no assurance that we would be able to raise cash by these means. This is known as the "residency test." We are a public limited company incorporated under the laws of England and Wales. Any such ordinary shares are evidenced by a receipt issued by the depositary. Such changes could adversely affect our financial condition and results of operations. 45Legal claims and proceedings could adversely affect our business.
